Your browser is no longer supported. Please, upgrade your browser.
OSMT Osmotica Pharmaceuticals plc daily Stock Chart
Osmotica Pharmaceuticals plc
Index- P/E- EPS (ttm)-2.93 Insider Own5.00% Shs Outstand58.86M Perf Week9.88%
Market Cap328.53M Forward P/E- EPS next Y-0.58 Insider Trans0.00% Shs Float15.95M Perf Month-12.80%
Income-155.40M PEG- EPS next Q-0.20 Inst Own44.30% Short Float4.80% Perf Quarter-13.22%
Sales211.60M P/S1.55 EPS this Y-113.50% Inst Trans-3.73% Short Ratio1.28 Perf Half Y43.04%
Book/sh2.22 P/B2.45 EPS next Y14.70% ROA-32.80% Target Price9.33 Perf Year51.39%
Cash/sh2.33 P/C2.34 EPS next 5Y- ROE-117.10% 52W Range2.81 - 9.67 Perf YTD-22.03%
Dividend- P/FCF5.88 EPS past 5Y- ROI-66.20% 52W High-45.19% Beta-
Dividend %- Quick Ratio2.80 Sales past 5Y- Gross Margin57.30% 52W Low88.61% ATR0.32
Employees379 Current Ratio3.20 Sales Q/Q-34.80% Oper. Margin-72.20% RSI (14)47.43 Volatility5.69% 5.76%
OptionableNo Debt/Eq2.05 EPS Q/Q90.70% Profit Margin-73.50% Rel Volume0.64 Prev Close5.45
ShortableYes LT Debt/Eq2.05 EarningsAug 11 AMC Payout- Avg Volume596.70K Price5.30
Recom1.80 SMA20-2.25% SMA50-7.70% SMA200-3.60% Volume194,109 Change-2.75%
Mar-18-20Initiated SunTrust Buy $8
Mar-06-20Initiated SVB Leerink Outperform $10
Jun-11-19Initiated Barclays Overweight $11
Nov-12-18Initiated Wells Fargo Outperform
Nov-12-18Initiated RBC Capital Mkts Outperform $17
Nov-12-18Initiated Jefferies Buy $21
Sep-02-20 04:30PM  
Aug-20-20 02:30PM  
Aug-12-20 12:01AM  
Aug-11-20 05:07PM  
Aug-06-20 08:00PM  
Jul-28-20 06:50AM  
Jul-20-20 06:50AM  
Jul-14-20 11:46AM  
Jul-13-20 09:52PM  
Jul-10-20 04:39PM  
Jul-09-20 08:09AM  
Jun-30-20 06:50AM  
Jun-23-20 08:46AM  
Jun-16-20 04:30PM  
May-27-20 04:30PM  
May-26-20 04:30PM  
May-15-20 10:12AM  
May-14-20 09:31AM  
May-13-20 05:08PM  
May-12-20 05:35PM  
May-08-20 01:30PM  
May-07-20 12:30PM  
Mar-18-20 04:05PM  
Mar-12-20 06:00PM  
Mar-03-20 06:50AM  
Feb-17-20 11:22AM  
Jan-18-20 05:09PM  
Jan-16-20 07:22AM  
Jan-08-20 08:40PM  
Jan-06-20 06:50AM  
Dec-23-19 11:40AM  
Dec-10-19 11:50AM  
Dec-06-19 11:40AM  
Nov-30-19 11:38AM  
Nov-27-19 07:44AM  
Nov-25-19 06:09AM  
Nov-22-19 09:48AM  
Nov-21-19 12:15PM  
Nov-20-19 09:30AM  
Nov-18-19 08:49AM  
Nov-14-19 04:05PM  
Nov-08-19 01:00PM  
Oct-28-19 03:50PM  
Sep-27-19 06:50AM  
Sep-18-19 06:50AM  
Sep-17-19 06:50AM  
Sep-04-19 06:50AM  
Aug-28-19 04:30PM  
Aug-22-19 01:06PM  
Aug-08-19 04:05PM  
Aug-01-19 04:30PM  
Jul-02-19 09:03PM  
May-30-19 04:30PM  
May-23-19 12:05PM  
May-14-19 04:30PM  
May-09-19 04:01PM  
May-07-19 08:20AM  
May-06-19 04:30PM  
May-02-19 05:00PM  
Apr-12-19 12:45PM  
Apr-11-19 12:05PM  
Apr-08-19 03:06PM  
Apr-02-19 04:41PM  
Mar-29-19 02:17PM  
Mar-28-19 11:54AM  
Mar-27-19 04:05PM  
Mar-13-19 07:07PM  
Dec-27-18 07:00AM  
Dec-03-18 04:30PM  
Nov-08-18 04:01PM  
Nov-05-18 07:00AM  
Oct-18-18 02:51PM  
Oct-11-18 12:27PM  
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone, a chlorzoxazone scored tablet for muscle spasms; ConZip, a tramadol hydrochloride extended-release capsule to treat pain; and Arbaclofen tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity. It also provides women's health products, including Divigel for menopause, as well as OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods; and RVL-1201, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorder and social anxiety disorder; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; and prescription prenatal vitamins for treating nutritional requirements during pregnancy, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Harsaul Foundation10% OwnerJan 13Buy5.001,250,0006,250,00022,485,297Jan 15 04:54 PM
Altchem Ltd10% OwnerJan 13Buy5.001,250,0006,250,00022,485,297Jan 15 04:39 PM
Venkataraman SriramDirectorJan 13Buy5.001,250,0006,250,00015,730,864Jan 15 04:13 PM
Burgstahler David FDirectorJan 13Buy5.001,250,0006,250,00015,730,864Jan 15 04:11 PM
Avista Capital Partners III GP10% OwnerJan 13Buy5.001,250,0006,250,00015,730,864Jan 15 04:11 PM